1351438-75-9

Dapagliflozin-3-O-β-D-glucuronide is a metabolite of dapagliflozin . Dapagliflozin is a first generation selective sodium glucose cotransporter (SGLT) 2 inhibitor that blocks glucose transport. Dapagliflozin is metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A9 to dapagliflozin-3-O-β-D-glucuronide, which is 2,600-fold less potent than the parent compound with regard to SGLT2 inhibition.

Dapagliflozin 3-O-β-D-Glucuronide is a metabolite of Dapagliflozin (D185380) which is a sodium-glucose transporter 2 inhibitor.

[1] EDWARD C. CHAO  Robert R H. SGLT2 inhibition — a novel strategy for diabetes treatment[J]. Nature Reviews. Drug Discovery, 2010, 9 7: 551-559. DOI: 10.1038/nrd3180
[2] J-S VAN DER WALT. A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment[J]. CPT: Pharmacometrics & Systems Pharmacology, 2013, 2 5: 1-9. DOI: 10.1038/psp.2013.20